BioSpace News Archive

Sutro Biopharma, Inc. announced that on March 1, 2023, the Compensation Committee of Sutro’s Board of Directors granted to Anne Borgman, M.D. 175,000 shares of Sutro Biopharma stock options and 150,000 restricted stock units of Sutro common stock in connection with her appointment as Sutro’s Chief Medical Officer and granted 10,000 RSUs of Sutro common stock to one other new employee.

HilleVax, Inc. reported financial results for the year ended December 31, 2022, highlighted recent program progress, and outlined key upcoming milestones for HIL-214, the company’s investigational virus-like particle based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis.

Connect Biopharma Holdings Limited announced that post hoc data analysis from the Phase 2b CBP-201 global trial in moderate-to-severe atopic dermatitis showed that CBP-201 led to rapid and sustained improvement in AD signs and symptoms across all four body regions, with both 2-week and 4-week dosing regimens, compared to placebo, as early as Week 2 and continuing through the 16-week study.

PURE Bioscience, Inc., creator of the patented non-toxic silver dihydrogen citrate antimicrobial, reported financial results for the fiscal second quarter and six-month period ended January 31, 2023.

RELIEF THERAPEUTICS Holding SA announced the Company will present the results of pre-clinical research evaluating the metabolic impact of PKU GOLIKE® on nitrogen balance, muscle strength and glucose.

Keymed Biosciences Inc. announced its 2022 annual results.

IRLAB Therapeutics AB announced that it will present new data in an oral presentation and hold three poster presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD ™ 2023, held on March 28- April 1, 2023, in Gothenburg, Sweden.

Biophytis SA annouces that it will change the ratio of its American Depositary Shares to Biophytis ordinary shares from one ADS representing 10 Shares, to one ADS representing 100 Shares.

Medivir AB announces that data from the company’s leading program fostroxacitabine bralpamide and its potential effect on hepatocellular carcinoma, will be presented at the American Association for Cancer Research Annual Meeting, on April 14-19, in Orlando, USA.

NRx Pharmaceuticals, Inc. today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Thursday, March 30, 2023, via press release.